Adam van Dyke

Adam Van Dyke, PhD, currently serves as the AVP of Innovation & Translational Development at Fox Chase Cancer Center, leading global business development and licensing initiatives to commercialize technological innovations derived from research. Prior experience includes working as Chief Operations Officer at Early Charm, where responsibilities encompassed managing a diverse portfolio of companies and implementing strategic initiatives that drove revenue growth and operational efficiency. Additional roles include Life Science Officer (Interim) and Principal - Blue Economy, where Adam focused on oncology therapeutics and developing blue economy technology companies. As a former Co-founder and CEO of Asulon Therapeutics Inc., Adam gained extensive experience in biopharma operations and drug development. Educational credentials include a PhD in Neuroscience from the University of Maryland, Baltimore, and a Master's in Neuroscience from the University of Hartford.